Most of the cell lines in our panel expressed relatively low levels of HLA-E as compared to the levels observed in vivo in myeloma patients and in mice, and therefore, we questioned whether a higher, more clinically relevant level of HLA-E expression would inhibit degranulation of activated NKG2A+ NK cells. The gene discussed is KLRC1; the disease is plasma cell myeloma.